Search Results

Ultivue, Inc. and, the Translational Research Unit platform of University of Bern announce a collaborative agreement to promote multiplexed immunofluorescence assays and the use of next generation TMAs to unlock spatial analysis in scientific research and improve the quality of TMAs integrated in clinical and translational research.

Ultivue, Inc., an industry leader in multiplexing assays and analytics solutions for tissue biomarker studies, announced multiple collaborations for AI-powered spatial phenomics solutions for translational research groups and Biopharma.

Keen Eye and Ultivue announce a collaborative agreement to promote multiplexed immunofluorescence (mIF) assays and scalable AI applications to unlock spatial analysis in clinical research.

Ultivue, an industry leader in multiplexing tools for tissue biomarker analysis, will participate in the Stifel 2021 Virtual Healthcare Conference to be held November 15th – 17, 2021

Ultivue, Inc. and Sirona Dx announced a co-marketing agreement to deliver tissue-based spatial multiplexed immunophenotyping solutions for translational research groups and Biopharma.

Ultivue announces the addition of Steve Pemberton in the role of SVP Commercial Development, as the company adds to its growing executive team.

Ultivue, Inc. and Aignostics GmbH announced a partnership to collaborate on the co-development of AI-powered spatial multiplexed immunophenotype solutions for translational research groups and Biopharma.

Ultivue, Inc. today announced that data from its FlexVUE™ formatting for panel design and its newest mouse panel offering for multiplex immunofluorescence (mIF) and spatially resolved biomarker analysis will be presented at the upcoming American Association for Cancer Research (AACR),

Ultivue announces the addition of two independent board members, Fenel Eloi and Mary Pat Lancelotta, to help strengthen its position as a leader in advancing precision medicine solutions by accelerating tissue biomarker discovery and validation.